Compare Davita Inc (DVA) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Shell PLC — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Shell PLC trades at $99.49 (market cap $284.34B). The key difference: Shell PLC is far larger — about 25.2× Davita Inc's market cap, and Shell PLC pays a 3.12% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Shell PLC for 90 Days on average.
| DVA | SHEL | |
|---|---|---|
Market Cap | $11.29B | $284.34B |
Volume | 582,204 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $240.96 | $100.20 |
52-Week Low | $103.87 | $70.31 |
Typical Hold Time | 113 Days | 90 Days |
Enterprise Value | $24.01B | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Shell (SHEL) trades at $96.85, down 0.79% on the day, with strong technical momentum indicated by bullish moving averages and a 52-week high near $99.16. The company shows solid fundamentals with a P/E of 10.71 and ROE of 14.35%, while recent earnings beat expectations in Q1 and Q2 2026. Key developments include the approval of LNG Canada Phase 2 expansion, doubling export capacity, and strategic portfolio optimization through asset divestments.
Outlook remains positive with analyst consensus at Buy (61.5%) and a $102.53 price target, though risks include volatile energy prices and execution challenges in major projects. The stock offers value through attractive valuation metrics and growth in LNG operations, supported by strong cash flow generation despite recent revenue declines from 2022 peaks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
